Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents

Published:2007-11 Issue:11 Volume:13 Page:1323-1332
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Nesbitt Andrew,Fossati Gianluca,Bergin Marianne,Stephens Paul,Stephens Sue,Foulkes Roly,Brown Derek,Robinson Martyn,Bourne Tim

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference30 articles.

1. Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

2. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

3. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

4. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

5. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease

Cited by 408 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Escherichia coli in the production of biopharmaceuticals;Biotechnology and Applied Biochemistry;2024-09-08

2. Certolizumab-induced sarcoidosis in a patient with psoriatic arthritis – a case report and review of literature;Rheumatology International;2024-08-24

3. The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors;2024-07-30

4. Treatment options for necrotizing scleritis in rheumatoid arthritis patients;Expert Review of Ophthalmology;2024-07-23

5. Biologics for Psoriasis;Dermatologic Clinics;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3